Negotiations over reinsurance, cost sharing for insurers stall in Hyde Amendment dispute; drug policy experts say more money is needed if leaders want to combat opioids for real; Supreme Court hears free speech case on abortion clinics.
In a blow to insurers, negotiations to fund reinsurance and cost-sharing reductions in the omnibus spending bill stalled Monday night in a funding dispute over abortion known as the Hyde Amendment, Modern Healthcare reported. Two analyses have projected that that reinsurance could lower premiums by at least 40%. The spending bill may be the last chance to stabilize the insurance markets before rates are set for 2019. The Hyde Amendment has never been applied to the Affordable Care Act, which was passed 8 years ago this week.
There’s tough talk on opioids from both President Donald Trump and Congress this week, but policy experts say the talk has to be matched with money—say, about $10 billion a year, if the United States wants to get serious about fighting the crisis, Kaiser Health News reported. Trump gave a speech on the issue Monday, calling for the death penalty for dealers, and Congress will embark on a series of hearings this week. However, drug policy experts said more meaningful action is needed to fight the problem, which has cost an estimated $1 trillion in premature deaths, healthcare costs and lost wages since 2001.
The Supreme Court hears oral arguments today in the biggest abortion case of the year, Politico reported. The California case centers on free speech and is brought by
anti-abortion “crisis pregnancy centers” that argue that a 2015 state law requiring them to tell women about free and low-cost abortion options violates their First Amendment rights. The law also requires those centers that aren’t licensed to provide medical care to post that clearly. The state of California and abortion rights supporters say the law simply requires the centers to display a written notice about abortion access.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More